Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zevalin Consolidation in Elderly DLBCL After CHOP21-R
NCT00850512Phase 2Completed
- Sponsor
- Alma Mater Studiorum – Università di Bologna
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ibritumomab tiuxetan in diffuse large B-cell lymphoma (DLBCL), sponsored by Alma Mater Studiorum – Università di Bologna. Primary endpoints: Overall Response Rate and Complete Response Rate. Status: completed.
02
Drugs
ibritumomab tiuxetan
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT00850512.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00850512.